zasocitinib
takeda
['psoriasis', 'ndi-034858']
new data presented at #aad2023 showed that an oral tyk2 inhibitor (ndi-034858) led to positive results for psoriasis patients in a recent phase 2b trial. learn more about the late-breaking data here: #psoriasis #aad23
Clinical News for Connected Physicians. Everything you need to enhance your clinical approach to improving patient care.